BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14734674)

  • 21. Direct comparison of F-18-FDG PET and ultrasound in the follow-up of patients with squamous cell cancer of the head and neck.
    Goerres GW; Haenggeli CA; Allaoua M; Albrecht SR; Dulguerov P; Becker M; Allal AS; Lehmann W; Slosman DO
    Nuklearmedizin; 2000 Dec; 39(8):246-50. PubMed ID: 11189902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
    Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
    Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
    Andrade RS; Heron DE; Degirmenci B; Filho PA; Branstetter BF; Seethala RR; Ferris RL; Avril N
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1315-22. PubMed ID: 16750327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorodeoxyglucose imaging using a coincidence gamma camera to detect head and neck squamous cell carcinoma and response to chemotherapy.
    Périé S; Montravers F; Kerrou K; Angelard B; Tassart M; Talbot JN; Lacau St Guily J
    Ann Otol Rhinol Laryngol; 2002 Sep; 111(9):763-71. PubMed ID: 12296328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of positron emission tomography in occult primary head and neck cancers.
    Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
    Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy.
    Berlangieri SU; Brizel DM; Scher RL; Schifter T; Hawk TC; Hamblen S; Coleman RE; Hoffman JM
    Head Neck; 1994; 16(4):340-6. PubMed ID: 8056579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
    Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
    Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
    Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
    Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
    Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.
    Brun E; Kjellén E; Tennvall J; Ohlsson T; Sandell A; Perfekt R; Perfekt R; Wennerberg J; Strand SE
    Head Neck; 2002 Feb; 24(2):127-35. PubMed ID: 11891942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography.
    Lowe VJ; Dunphy FR; Varvares M; Kim H; Wittry M; Dunphy CH; Dunleavy T; McDonough E; Minster J; Fletcher JW; Boyd JH
    Head Neck; 1997 Dec; 19(8):666-74. PubMed ID: 9406745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma.
    Connell CA; Corry J; Milner AD; Hogg A; Hicks RJ; Rischin D; Peters LJ
    Head Neck; 2007 Nov; 29(11):986-95. PubMed ID: 17563906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
    Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.